Spina Bifida in-Utero Market Report 2025

The spina bifida in utero market size has grown strongly in recent years. It will grow from $2.42 billion in 2024 to $2.66 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth during the historic period can be attributed to the rising prevalence of spina bifida, increased awareness of fetal surgery, higher maternal age and associated pregnancy risks, growing healthcare expenditures, and advancements in research and development within fetal medicine.

The spina bifida in utero market size is expected to see strong growth in the next few years. It will grow to $3.77 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The projected growth during the forecast period can be attributed to rising awareness of prenatal diagnosis and treatment, greater adoption of minimally invasive procedures, increased government initiatives and funding, the expansion of healthcare infrastructure in emerging markets, and the growing number of specialized fetal surgery centers. Key trends for this period include advancements in prenatal screening and diagnostics, technological innovations in minimally invasive surgical techniques, the development of biomaterials for fetal surgery, innovations in amniotic fluid-based therapies, and the adoption of artificial womb technology to support fetal development.

The growth of healthcare facilities is expected to drive the expansion of the spina bifida in-utero market. Healthcare facilities refer to the essential infrastructure, systems, and resources required to provide effective medical services. The expansion of healthcare infrastructure is primarily attributed to advancements in medical technology, such as telemedicine, robotic surgery, and AI-driven diagnostics, all of which require updated facilities, specialized equipment, and improved healthcare delivery systems to enhance patient outcomes and efficiency. These healthcare facilities support spina bifida in-utero by ensuring access to evidence-based therapies, skilled medical professionals, and innovative treatment options, all of which improve healing outcomes and quality of life for patients. For example, the American Hospital Association, a US-based non-profit organization, reported that the total number of hospitals in the United States reached 6,120 in 2024, a rise from 6,093 hospitals in 2022. This growth in healthcare infrastructure is thus contributing to the development of the spina bifida in-utero market.

Companies operating in the spina bifida in-utero market are focusing on establishing innovative centers, such as surgery centers, that incorporate advanced imaging and minimally invasive techniques for fetal interventions. Surgery centers are specialized facilities where surgical procedures are performed on an outpatient basis, eliminating the need for hospital admission. For instance, in January 2025, Wadia Hospital, located in India, opened a center offering fetal surgery for open spina bifida. The facility integrates state-of-the-art surgical techniques and a multidisciplinary approach to enable early intervention, which can reduce complications and improve long-term outcomes for infants affected by the condition. The center emphasizes surgical precision and high-quality patient care, offering hope for families dealing with the challenges of open spina bifida.

In March 2024, Lilavati Hospital, an India-based multi-specialty healthcare institution, formed a partnership with the Medical University of Silesia. This collaboration aims to establish a fetal surgery department to provide advanced in-utero treatment for birth defects, including spina bifida. The Medical University of Silesia, located in Poland, is known for its expertise in fetal surgery techniques and in-utero treatments for various conditions.

Major players in the spina bifida in-utero market are Mayo Clinic, GE HealthCare, UC San Francisco, Children’s Health, Memorial Hermann Health System, Oregon Health & Science University, Seattle Children's, Texas Children’s, Children's Hospital of Philadelphia, UW Health, UC Davis, UCSF Health, Burjeel Hospital, UT Physicians, Thieme Group, Riley Children's Health, Yale Medicine, Focused Ultrasound Foundation, Petals Health, Brown University Health.

North America was the largest region in the spina bifida in utero market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in spina bifida in-utero report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the spina bifida in-utero market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Spina bifida in-utero refers to a prenatal surgical procedure aimed at repairing spina bifida, a neural tube defect in which the spine and spinal cord fail to develop properly. Performed before birth, this surgery helps reduce complications such as hydrocephalus, enhances mobility, and improves neurological outcomes. By closing the defect early, it protects the exposed spinal cord from further damage, ultimately improving the child's quality of life compared to postnatal repair.

The primary types of spina bifida in-utero include myelomeningocele, meningocele, and occulta. Myelomeningocele is the most severe form, characterized by the protrusion of the spinal cord and meninges through an opening in the spine. Diagnosis methods include ultrasound, magnetic resonance imaging (MRI), and amniocentesis. Treatment options consist of in-utero surgery, postnatal surgery, and medication management. These interventions are utilized in various healthcare settings, including hospitals, specialty clinics, and ambulatory surgical centers.

The spina bifida in-utero market research report is one of a series of new reports that provides spina bifida in-utero market statistics, including spina bifida in-utero industry global market size, regional shares, competitors with a spina bifida in-utero market share, detailed spina bifida in-utero market segments, market trends and opportunities, and any further data you may need to thrive in the spina bifida in-utero industry. This spina bifida in-utero market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The spina bifida in-utero market consists of revenues earned by entities providing services such as physical therapy planning, genetic counseling, and multidisciplinary team support. The market value includes the value of related goods sold by the service provider or included within the service offering. The spina bifida in-utero market also includes sales of sales of anesthesia and maternal support equipment, fetal monitoring devices, and biodegradable adhesives and sealants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.